about
Biological and clinical features of trisomy 21 in adult patients with acute myeloid leukemia.Patient-driven discontinuation of tyrosine kinase inhibitors: single institution experienceOcular granulocytic sarcoma: a case report and literature review of ocular extramedullary acute myeloid leukemiaThe achievement of a 3-month complete cytogenetic response to second-generation tyrosine kinase inhibitors predicts survival in patients with chronic phase chronic myeloid leukemia after imatinib failure.Prognostic implications of chromosome 17 abnormalities in the context of monosomal karyotype in patients with acute myeloid leukemia and complex cytogeneticsModest activity of pomalidomide in patients with myelofibrosis and significant anemiaThe clinical significance of achieving different levels of cytogenetic response in patients with chronic phase chronic myeloid leukemia after failure to front-line therapy: is complete cytogenetic response the only desirable endpoint?Malignancies occurring during therapy with tyrosine kinase inhibitors (TKIs) for chronic myeloid leukemia (CML) and other hematologic malignancies.The achievement of an early complete cytogenetic response is a major determinant for outcome in patients with early chronic phase chronic myeloid leukemia treated with tyrosine kinase inhibitorsImproved survival in chronic myeloid leukemia since the introduction of imatinib therapy: a single-institution historical experienceEUTOS score is not predictive for survival and outcome in patients with early chronic phase chronic myeloid leukemia treated with tyrosine kinase inhibitors: a single institution experience.Analysis of outcomes in adolescents and young adults with chronic myelogenous leukemia treated with upfront tyrosine kinase inhibitor therapy.Novel approaches in the treatment of systemic mastocytosis.Nilotinib therapy in chronic myelogenous leukemia.Outcome after failure of second generation tyrosine kinase inhibitors treatment as first-line therapy for patients with chronic myeloid leukemiaAntagonistic activities of the immunomodulator and PP2A-activating drug FTY720 (Fingolimod, Gilenya) in Jak2-driven hematologic malignanciesAssessment at 6 months may be warranted for patients with chronic myeloid leukemia with no major cytogenetic response at 3 months.Similar outcome of patients with chronic myeloid leukemia treated with imatinib in or out of clinical trials.New agents in the treatment of chronic myelogenous leukemia.HCVAD plus imatinib or dasatinib in lymphoid blastic phase chronic myeloid leukemia.Tyrosine kinase inhibitors as initial therapy for patients with chronic myeloid leukemia in accelerated phase.Experimental therapeutics for patients with myeloproliferative neoplasias.Bafetinib, a dual Bcr-Abl/Lyn tyrosine kinase inhibitor for the potential treatment of leukemia.The economic burden of pleural effusions in patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors.Dynamics of chronic myeloid leukemia response to long-term targeted therapy reveal treatment effects on leukemic stem cells.Antileukemia activity of the combination of an anthracycline with a histone deacetylase inhibitor.Management of cytopenias in patients with myelofibrosis treated with ruxolitinib and effect of dose modifications on efficacy outcomes.Peripheral blood blast clearance is an independent prognostic factor for survival and response to acute myeloid leukemia induction chemotherapyGranulocyte-colony-stimulating factor (filgrastim) may overcome imatinib-induced neutropenia in patients with chronic-phase chronic myelogenous leukemia.Imatinib mesylate therapy may overcome the poor prognostic significance of deletions of derivative chromosome 9 in patients with chronic myelogenous leukemia.Ponatinib in Philadelphia chromosome-positive leukemias.
P50
Q33914289-3018760B-D574-4343-8937-1F890C06E176Q34022125-46C0D52D-6F54-4320-A154-9E35390A3B67Q34117308-50CCA012-F9D9-4FE0-8F22-D37999149DABQ34163101-A99A6CA3-22DC-4D6B-829E-F4FD94595EF3Q34205736-7572FEB7-08F9-40AE-B763-8F747AA3F5C0Q34512203-D52D79B8-8FBF-4FE2-A324-B58C00C82454Q35548766-CA4D1E0C-C74E-4F1B-8387-75A4BD584F2CQ35794105-334828C9-C526-4203-8413-932C396AB7FBQ35794115-7B31C7F0-F1AF-4A83-9738-4819B3B5739DQ35849204-7A28A7B9-BA7E-4BDD-B537-234338E6E93AQ35995232-03843665-324A-4BB2-8F95-04642BBDC9CBQ36094702-7870A42D-DB0E-4A1A-A609-2DB8ADF99602Q36583570-36871948-DF26-4299-BD24-6A468981EACBQ36995184-86BFCB41-F202-48F8-BBCD-1A5A2103818AQ37117967-91F1FC83-7D66-406D-9909-724C51D06633Q37169105-77F2775C-4F92-4297-9D3D-779281284CF3Q37273161-0ADDD3BC-1FCB-4F0E-BEE6-BB2F639088E9Q37329232-548CEBD9-469B-498F-90F4-40F587EDE3C9Q37624951-BB8ED92C-B995-492B-9B56-CE08EF0BA74AQ37625289-C306E9BA-104B-4E82-99C9-B993B212B772Q37647076-9EDC6EE8-DC16-4B79-8BF7-74161CB0D5E0Q37797983-3FD6E62C-79F4-4B16-86EA-DE33148D4B57Q37820494-A8898472-AF5F-4A85-8C62-D9A8BD84CD50Q38010218-A4A47E2D-2F13-41F4-8DAA-322C615661B8Q41765680-2637DBA8-7184-4CE5-974D-C3EB1FA9C606Q41778895-DA7FAF1E-940D-4611-9CBA-AB01395A38B4Q41836418-CBC15DCE-5DA6-4B73-9DA6-8224038EF3C5Q42365051-91AED0FA-32D3-4431-95B8-CC731EBA6C00Q44937081-D50F0864-AC29-4FBE-B31C-B31E7E761621Q45168867-72B2F799-9160-43DB-86DC-4C987CC15FE8Q54379467-20A9A5D2-A1E4-4570-84F8-9375FB9CB3E3
P50
name
Alfonso Quintas-Cardama
@ast
Alfonso Quintas-Cardama
@en
Alfonso Quintas-Cardama
@nl
type
label
Alfonso Quintas-Cardama
@ast
Alfonso Quintas-Cardama
@en
Alfonso Quintas-Cardama
@nl
prefLabel
Alfonso Quintas-Cardama
@ast
Alfonso Quintas-Cardama
@en
Alfonso Quintas-Cardama
@nl